The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.
The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.
The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.
CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.
CHB delivers targeted exposure to an emerging theme and industry.
In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.
| Ticker | CHB |
| Inception Date | 09/22/20 |
| CUSIP | 37954Y251 |
| ISIN | US37954Y2515 |
| Bloomberg Index Ticker | SOLCHB |
| Primary Exchange | Nasdaq |
| Number of Holdings | 31 |
| Net Assets | $2,311,117 |
| Net Asset Value (NAV) | $15.41 |
| Shares Outstanding | 150,000 |
| Total Expense Ratio | 0.65% |
| 30-Day SEC Yield | N/A |
| Distribution Frequency | Semi-Annually |
Cumulative %Data as of month-end (10/31/20) |
Fund NAV | Market Price | Index |
|---|---|---|---|
| Year-to-Date | -- | -- | -- |
| 1 Month | 1.44% | 1.68% | 1.50% |
| 3 Months | -- | -- | -- |
| 6 Months | -- | -- | -- |
| Since Inception | 2.98% | 4.11% | 3.07% |
Cumulative %Data as of quarter-end (09/30/20) |
Fund NAV | Market Price | Index |
|---|---|---|---|
| Since Inception | 1.52% | 2.39% | 1.54% |
Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.
| Return on Equity | 5.10% | |
| Weighted Avg. Market Cap | 9,744 M | |
| 2019 | 2020 | |
| Price-to-earnings | 524.97 | 135.52 |
| Price-to-book value | 7.05 | 6.90 |
Source: AltaVista Research, LLC
| Net Assets (%) | Ticker | Name | SEDOL | Market Price ($) | Shares Held | Market Value ($) |
|---|---|---|---|---|---|---|
| 9.00 | 2963 HK | WUXI BIOLOGICS CAYMAN INC | BN92PQ8 | 10.75 | 19,350 | 208,033.65 |
| 7.78 | 000661 C2 | CHANGCHUN HIGH-A | BD5CDB3 | 54.50 | 3,300 | 179,862.75 |
| 7.64 | BGNE | BEIGENE LTD-ADR | BYYWPW6 | 284.17 | 621 | 176,469.57 |
| 7.42 | 300142 C2 | WALVAX BIOTECHNOLOGY CO-A | BD5CG36 | 6.67 | 25,700 | 171,512.32 |
| 7.14 | 300601 C2 | SHENZHEN KANGT-A | BFY8HT2 | 22.69 | 7,271 | 164,965.98 |
| 5.58 | ZLAB | ZAI LAB LTD-ADR | BD9GVY0 | 104.31 | 1,237 | 129,031.47 |
| 4.69 | 300357 C2 | ZHEJIANG WOLWO-A | BFY8GY0 | 9.27 | 11,700 | 108,486.16 |
| 4.47 | 1177 HK | SINO BIOPHARMACEUTICAL | B00XSF9 | 1.02 | 101,700 | 103,369.92 |
| 4.45 | 300676 C2 | BGI GENOMICS CO LTD-A | BFY8H58 | 20.02 | 5,138 | 102,883.02 |
| 3.82 | 002007 C2 | HUALAN BIOLOGI-A | BD5CL19 | 6.59 | 13,400 | 88,282.26 |
| Holdings are subject to change. | ||||||
Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.
Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.
Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.
Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.
Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.
888-493-8631
Leave us a note